AzTrials
AzTrials

OSANCT04179942

Fractional Exhaled Nitric Oxide and CRP Levels in Egyptian Patients With Obstructive Sleep Apnea Syndrome

A study testing Fractional exhaled nitric oxide and CRP levels in people with OSA, run by Mansoura University at 1 site in Egypt.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

Obstructive sleep apnea syndrome (OSAS) was associated with upper and lower respiratory tract inflammation, Fractional exhaled nitric oxide (FeNO) proposed as a marker of airway inflammation, few studies were done on the impact of continuous positive airway pressure (CPAP) on FeNO. Read more about this study

Who is it for?
Ages 18 to 60 yearsHealthy volunteers can take part
Conditions the study is for
OSA
What is being tested?
Fractional exhaled nitric oxide and CRP levels
Could I receive a placebo?
Yes, some participants may receive a placebo
How many people
27 participants
Where
1 siteEgypt
Study dates
6 Jun 2017to 20 Nov 2018
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 60 years
  • All sexes
  • Healthy volunteers accepted
  • Adult

Who may be able to join

  • fractional exhaled nitric oxide and Hs-CRP were measured next morning of PSG, CPAP for moderate to severe OSA patient was advised with measurement of FeNO and Hs-CRP after 3months of CPAP
  • were ≥ 18 years old,
  • non-smokers and
  • excluded from any inflammatory disorders (allergy, bronchial asthma, gastro-esophageal reflux disease, cardiovascular diseases, and cerebrovascular diseases) or use of any regular medication including (nasal/inhaled/oral corticosteroids, antihistaminic, cysteinyl leukotriene receptor inhibitors),
  • or had upper or lower respiratory tract infection 2 weeks prior to sampling.
  • Control healthy subjects were also free from any sleep disorders symptoms. Cases were recruited from Sleep-disordered breathing unit out Patient Clinic in pulmonary medicine department - Mansoura University - Egypt.

Who cannot join

  • smokers
  • inflammatory disorders
  • cardiovascular disease,
  • on regular medication including (nasal/inhaled/oral corticosteroids, antihistaminic, cysteinyl leukotriene receptor inhibitors) -

Trial locations and contacts

1 site in 1 country.

Egypt1 site
  • Mansoura Faculty Chest Hospital

    Al Mansurah

Other trials in Egypt

About this study

Obstructive sleep apnea syndrome (OSAS) was associated with upper and lower respiratory tract inflammation, Fractional exhaled nitric oxide (FeNO) proposed as a marker of airway inflammation, few studies were done on the impact of continuous positive airway pressure (CPAP) on FeNO.

Aim of the work: to study the impact of continued positive airway pressure therapy on exhaled NO and using Hs-CRP as a marker of inflammation in obstructive sleep apnea syndrome.

Patient and Methods: This study is a case-control study including participants were newly diagnosed as OSAS and control recruited from sleep outpatient clinic, full night PSG was done, fractional exhaled nitric oxide and Hs-CRP were measured next morning of PSG, CPAP for moderate to severe OSA patient was advised with measurement of FeNO and Hs-CRP after 3months of CPAP Keywords: FeNO; Hs-CRP; CPAP; OSA. This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

Read the detailed description

This study is a prospective 3 months follow up study including only (27) participants as a convenient sample for the cost limitations newly diagnosed as OSA and (10) healthy control.

inclusion characters All participants enrolled in this study

  1. were ≥ 18 years old,
  2. non-smokers and
  3. excluded from any inflammatory disorders (allergy, bronchial asthma, gastro-esophageal reflux disease, cardiovascular diseases, and cerebrovascular diseases) or use of any regular medication including (nasal/inhaled/oral corticosteroids, antihistaminic, cysteinyl leukotriene receptor inhibitors), or
  4. had an upper or lower respiratory tract infection 2 weeks prior to sampling. Control healthy subjects were also free from any sleep disorders symptoms. Cases were recruited from Sleep-disordered breathing unit out Patient Clinic in pulmonary medicine department - Mansoura University - Egypt. All participants in this study were evaluated by history taking with stress on OSAS questionnaires, anthropometric parameters measurement and spirometric pulmonary function (FEV1, FVC and FEV1/FVC ) all patients were subjected to laboratory, attended, full-night polysomnography using (SONMOscreenTMplus, SOMNOmedics, (Germany) with AASM standard montage, This included a standardized montage: two-channel electroencephalograms (EEG; C4/A1, C3/A2), bilateral electrooculogram (EOG), submental electromyogram (EMG), bilateral leg EMGs, and electrocardiography (ECG). Airflow was measured using a thermistor (Healthdyne Technologies), the respiratory effort was assessed by inductance plethysmography and oxygen saturation was recorded using a finger probe. The oxygen saturation signal was digitally sampled at 1 Hz and stored both on the PSG record and in a separate monitor for offline analysis. studies were interpreted according to the last manual scoring criteria. The cases were diagnosed as severe OSA according to the third international classification of sleep disorders. Then they were classified according to apnea-hypopnea index (AHI) into two main groups: cases (AHI ≥5) (n=) and control (AHI˂5) (n=10). Cases were classified into two subgroups into severe OSA (AHI ≥ 30) (n=34) and moderate OSA (AHI (15-30) mild (n=10).

On the next morning of the study 30 min after PSG, the blood sample was collected for measuring of high sensitivity C- reactive protein (HS-CRP) by (The Immunospec Hs-CRP) ELISA, based on the principle of a solid phase enzyme-linked immunosorbent assay [15]. The assay system utilizes a unique monoclonal antibody directed against a distinct antigenic determinant on the CRP molecule.

  1. fractional exhaled nitric oxide (FeNO) measurement: was measured by (NO breath®FeNO monitor-Bedfont scientific Ltd) according to international recommendations [16], with a single breath online method at constant flow of 50 mL/s or 12 seconds of exhalation of adults with a sensitivity of one part per billion (ppb) Calibration of the analyzer was automatically performed by the software. Briefly, after inhaling to total lung capacity, the subjects exhaled through a mouthpiece into an exhalation circuit. All subjects were asked to stop eating, drinking, and strenuous exercise for two hours prior to FeNO measurement.
  2. CPAP therapy and follow up: 22 of 27 patients with moderate and severe OSA were advised to use CPAP therapy after full-night CPAP titration study in accordance with AASM recommendations [17]Preliminary education and adaptation for CPAP was performed 1hour prior to the beginning of CPAP titration. An optimal titration study was defined as one in which an optimal CPAP pressure was reached that normalizes the AHI and eliminates snoring, desaturation, and arousals, and restores a normal flow contour [17] adjusted prescribed CPAP pressure after titration was administered during sleep for at least five hours per night, for at least five days per week for three consecutive months.
  3. follow up sessions after CPAP therapy: were adjusted 1,2 and 3 months after starting CPAP therapy for evaluation of patients response and compliance to CPAP, Adherence to the CPAP therapy was evaluated after revision of the download information from the CPAP device. Adherence was defined as CPAP use for an average of 4 h on ≥ 70% of the nights.
  4. (FeNO) was also measured in the three follow up visit with CPAP follow up, however, BMI, spirometric pulmonary function(FEV1, FVC, and FEV1/FVC ) and high sensitivity C- reactive protein (HS-CRP) were measured after 3 months in last follow up visit of the study.

Five patients from 27 were lost in follow up sessions because they did not use CPAP.

Then data were analyzed using SPSS version 16 for Windows® (SPSS Inc, Chicago, IL, USA). Qualitative variables were presented as numbers and percentages. Chi-square test or Fisher exact test of significance was for comparison between groups, as appropriate. Quantitative variables were presented as mean ±SD. They were tested for normality distribution by the Kolmogorov-Smirnov test. In normally distributed variables unpaired t-test (t) was used. In abnormally distributed variables independent Mann-Whitney test (Z) was used. P-value ≤0.05 was considered statistically significant. For the detection of cut off points, we use the receiver operating characteristic (ROC) curve. Sensitivity, Specificity values were used for studying the selected cut off point for validation as a screening tool.

Conditions
OSA
Being tested
Fractional exhaled nitric oxide and CRP levels
Keywords
FeNO; ;;, Hs-CRP, CPAP, OSA

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Fractional exhaled nitric oxide and CRP levelsDiagnostic test

    measurement of FeNO and Hs-CRP after 3months of CPAP

Study groups in NCT04179942
Study groupRoleWhat they receive
PatientsActive comparatorfull night PSG (polysomnogram) was done, fractional exhaled nitric oxide and Hs-CRP were measured
Receives: Diagnostic Test: Fractional exhaled nitric oxide and CRP levels
controlPlacebo comparatorCRP level was measured
Receives: Diagnostic Test: Fractional exhaled nitric oxide and CRP levels

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Full-night PSG was performed,

    Measurement of FeNO and Hs-CRP with three month intervals of CPAP

    Measured: one year

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted27 Nov 2019
  2. Study start6 Jun 2017
  3. Primary completion15 Aug 2018
  4. Study completion20 Nov 2018

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Diagnosis
Allocation
Non-randomised
Intervention model
Parallel groups
Masking
None (open label)
Enrolment
27 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT04179942
Sponsor's protocol ID
MS.16.06.82
Status last verified
Nov 2019
First submitted
19 Nov 2019
Last updated
3 Dec 2019
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
Undecided

Questions about this trial

What is this clinical trial studying?

A study testing Fractional exhaled nitric oxide and CRP levels in people with OSA, run by Mansoura University at 1 site in Egypt.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 6 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 3 Dec 2019. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Egypt. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Full-night PSG was performed, (time frame: one year). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 3 Dec 2019.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in